

## Bulletin from the Annual General Meeting of Nanexa

**On May 24, 2021, the Annual General Meeting of Nanexa AB (publ) was held. Due to the risk of spreading of Covid-19 and the authorities' regulations and advice, the Annual General Meeting was held only through advance voting (so-called postal voting) in accordance with temporary rules.**

At the meeting, it was decided to approve the presented income statement and balance sheet. At the meeting, it was also decided to carry forward the company's results in accordance with the Board's proposal in the annual report.

The Annual General Meeting resolved to discharge the board members and the CEO from liability.

At the meeting, it was decided that board fees shall be paid in the amount of SEK 260,000 to the Chairman of the Board, in the amount of SEK 230,000 to the Chairman of the Audit Committee and in the amount of SEK 130,000 each to other Board members who are not employees of the company. Furthermore, it was decided that auditors' fees shall be paid according to approved invoices.

The Annual General Meeting resolved to re-elect Göran Ando, Bengt Gustavsson, Urban Paulsson, Mårten Rooth, Otto Skolling and Magnus Westgren and to elect Birgit Stattin Norinder and Eva Nilsagård as new Board members. Göran Ando was re-elected Chairman of the Board.

Öhrlings PricewaterhouseCoopers AB was appointed auditor. Niclas Bergenmo will take over as chief auditor after Lars Kylberg.

It was resolved to establish a Nomination Committee prior to the 2022 Annual General Meeting and to establish instructions for the Nomination Committee in accordance with the proposal included in the notice convening the Annual General Meeting.

In accordance with the Board's proposal, it was resolved to change the wording of the Articles of Association's provisions regarding share capital (§ 4) and number of shares (§ 5).

The Annual General Meeting resolved to adopt the Board's proposals for authorizations for the Board to decide on rights issue and directed issue of shares respectively.

Finally, in accordance with the Board's proposal, the Annual General Meeting resolved to establish a warrant-based incentive program covering all employees in the company. However, the Nomination Committee's proposal to establish a warrant-based incentive program including some of the Board members did not receive the required majority.

The content of the resolutions is stated (in Swedish) in the Notice of the Annual General Meeting (Kallelse till Årsstämma).

**For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

**About Nanexa AB (publ)**

---

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

**Attachments**

---

[Bulletin from the Annual General Meeting of Nanexa](#)